New Clinical Study Examines Stem Cell Treatments for Diabetes
A new clinical report published in The Lancet Diabetes & Endocrinology examined the use of stem cell-derived islet therapy for advanced type 1 diabetes, offering important insights for patients researching stem cell therapy for diabetes and asking, “can type 1 diabetes be cured?” and “what is the real stem cell therapy success rate?” It represents early human experience using stem cells to replace damaged pancreatic cells responsible for insulin production. These experimental therapies focus on stem cell–derived islet cells designed to replace insulin-producing beta cells, which represents a different approach from mesenchymal stem cell (MSC) therapies used in many regenerative medicine clinics today.
This update breaks down what the study investigated, how the therapy was administered, and what the initial findings may mean for the future of regenerative diabetes treatment. For those who would like to review the complete data, the full study is available at the end of this page.
What This Clinical Study Reveals About Stem Cell Therapy for Diabetes
Parkinson’s Disease Stem Cell Treatment Study Using iPSC's
Type 1 diabetes is classified as an autoimmune disease in which immune cells mistakenly attack the insulin-producing beta cells of the pancreas. Specialized immune cells called T-cells identify these cells as a threat and trigger inflammatory processes that gradually destroy them. Because this immune response remains active, the body cannot naturally regenerate beta cells. This is why restoring insulin production is so challenging. Any regenerative strategy must consider both cellular replacement and immune system modulation.
A new study examined whether patient-matched and donor-derived stem cell–derived islet cells could safely support metabolic function in people with long-standing type 1 diabetes.
This research explores whether regenerative therapies can restore biological insulin regulation rather than simply manage insulin levels. While the study focuses on stem cell–derived islet cells designed to replace pancreatic beta cells, other approaches like mesenchymal stem cell (MSC) therapy are being studied for their ability to support immune balance and metabolic signaling.
How the Clinical Study on Donor Stem Cells Was Conducted
In the Phase 1-2 study:
- Researchers developed islet-like clusters of insulin-producing cells from stem cell sources.
- Participants received either autologous or allogeneic cell preparations via infusion.
- Patients were monitored for safety and metabolic effects afterward.
The study included only three participants. However, it represents one of the first reports of stem cell–derived islet therapy used clinically in humans with type 1 diabetes and complete beta cell deficiency.
This early-phase design focused on feasibility, safety, and preliminary biological signals, rather than definitive cure or broad clinical efficacy.
What the Researchers Found in This Stem Cell Study for Diabetes
The stem cell–derived islet cell infusions were successfully administered and tolerated by the participants. Because these therapies involve transplanting insulin-producing cells, immune protection of the transplanted cells is critical. By contrast, MSC-based regenerative therapies typically aim to influence inflammatory signaling and immune activity rather than replace pancreatic cells directly.
Did Participants Experience Improvement?
Yes, the researchers reported measurable biological improvements following transplantation.
After receiving stem cell–derived islet cells, participants showed:
- Evidence of insulin production where none had been detected before.
- Improvements in glucose regulation markers.
- Signs of partial restoration of beta-cell function.
However, outcomes varied between individuals, and the study did not establish permanent insulin independence for all participants. Follow-up duration was limited, and larger clinical trials are necessary to determine durability and broader effectiveness.
Participants showed early functional improvement, but the study does not confirm a cure for type 1 diabetes. Instead, it suggests stem cell–derived pancreatic cells may help restore insulin-producing activity in humans.
Understanding the Benefits of Stem Cells
Stem cells and stem cell-derived therapies are of interest in diabetes because they have the potential to:
- Differentiate into insulin-producing pancreatic cells.
- Augment or replace lost biological function.
- Interact with local signaling pathways that regulate glucose.
Rather than simply managing glucose levels, these therapies aim to restore physiological insulin regulation at the cellular level. Early research into stem cell-derived islets and similar regenerative strategies has shown that engineered cells can produce insulin and respond to glucose in controlled settings.
While the study examined stem-cell-derived pancreatic islet cells designed to replace insulin-producing beta cells, many regenerative clinics today focus on mesenchymal stem cells (MSCs). These cells do not directly replace pancreatic cells but may support immune modulation, inflammation reduction, and tissue signaling pathways that influence metabolic function.
For patients exploring the stem cell therapy success rate in clinical contexts, it’s important to recognize that early clinical science mostly measures biological function and feasibility.
The Challenge of Immune Rejection
One of the major scientific challenges in stem cell-derived islet therapy is immune rejection.
Because islet replacement therapies introduce insulin-producing cells into the body, they may be vulnerable to both immune rejection and recurrence of the autoimmune attack that originally destroyed pancreatic beta cells.
Some regenerative medicine approaches instead investigate mesenchymal stem cells (MSCs), which are being studied for their potential immunomodulatory properties that may influence inflammatory signaling rather than directly replacing pancreatic cells.
What This Means for Stem Cell Therapy in Mexico
Mexico has become a notable destination for advanced regenerative therapies, and many patients researching the best stem cell therapy in Mexico seek treatment options beyond conventional care. However, the quality of outcomes is closely tied to facility standards, clinical oversight, and evidence-based practice.
Key considerations include:
- Medical-grade sourcing and processing of stem cells.
- Physician-led administration and monitoring.
- Robust follow-up care.
- Clear communication about realistic outcomes.
While the Lancet Diabetes & Endocrinology study offers measurable early clinical experience, patients should be cautious about any provider who overstates results or promises cure-level outcomes. Stem cell research is advancing, but rigorous evidence and long-term trials are still underway.
TreVita’s Commitment to Evidence-Based Care
At TreVita, we believe patients deserve:
- Clear, scientifically grounded education.
- Responsible discussion of benefits and limitations.
- Medical oversight from experienced clinicians.
- Realistic expectations grounded in peer-reviewed research.
We follow developments in regenerative research, including early results like those reported in this Lancet Diabetes & Endocrinology study, to provide accurate, conservative guidance for patients exploring stem cell therapy for diabetes.
Research like this informs understanding of how stem cells might someday play a role in diabetes care, but it also highlights the importance of experienced clinical teams and high-quality facilities in determining long-term outcomes.
Interested in Learning More?
Understanding stem cell therapy for type 1 diabetes begins with science and realistic expectations. If you are exploring stem cell therapy for diabetes and want to understand whether regenerative treatments may support your condition, our team can review your medical history and determine whether you may be a candidate for treatment. At TreVita, patients receive transparent guidance, physician oversight, and access to advanced regenerative therapies in carefully controlled clinical environments.
We’ll continue to break down new clinical discoveries as they emerge, so you can stay informed, empowered, and grounded in science.
The information provided is for educational purposes only and is not intended to replace medical advice, diagnosis, or treatment.